Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-02-08
2011-02-08
Fetterolf, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S130000, C544S364000, C514S225500
Reexamination Certificate
active
07884107
ABSTRACT:
In its many embodiments, the present invention discloses novel compounds, as inhibitors of HDM2 protein methods for preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of treatment, prevention, inhibition, of one or more diseases associated with the HDM2 protein or P53 using such compounds or pharmaceutical compositions.
REFERENCES:
patent: 6403584 (2002-06-01), deLaszlo et al.
patent: 6645987 (2003-11-01), Chackalamannil et al.
patent: 2004/0259867 (2004-12-01), Fotouhi et al.
patent: 2004/0259884 (2004-12-01), Haley
patent: 2005/0037383 (2005-02-01), Taremi et al.
patent: 0 947 494 (1999-03-01), None
patent: 09 249566 (1997-09-01), None
patent: WO 00/15657 (2000-03-01), None
patent: WO 2004/080460 (2004-09-01), None
patent: WO 2007/070398 (2007-06-01), None
Ding et al. Emerging cancer therapeutic opportunities target DNA-repair systems. TRENDS in Pharmacological Sciences, vol. 27, No. 6, Published online May 2006.
Translation of JP 09-249566, Part 1.
Translation of JP 09-249566, Part 2.
Jordan, V.C. Nature Reviews: Drug Discovery, 2, 2003, p. 205.
Dorwald F. Zaragoza. Side Reviews in Organic Synthesis: A guide to successful synthesis design, Weinheim: Wiley-Vch, Verlag, GMBH & Co. KGaA, 2005, Preface.
Wolff et al. Burger's Medicinal Chemistry and Drug Discovery—Fifth Edition, New York: John Wiley & Songs, 1996, vol. 1, pp. 975-976.
Vippagunta et al. Advanced Drug Delivery Reviews, 48, 2001, p. 18.
Yang et al. Small molecular inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell. Jun. 2005.
Schaefer et al. Failure is not an option: learning from unsuccessful proof-of-concept trials. Drug Discovery Today, 2006, 13(21/22): 913-916.
Horig et al. Review: From bench to clinic and back: Perspective on the 1stIQPC Translational Research Conference. Journal of Translational Medicine, 2004, 2(44).
J.G. Cannon. Chapter Nineteen in Bruger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. I: Principles and Practice. Wiley-Interscience, 1995, pp. 783-802.
Freedman et al., “Nuclear Export Is Required for Degradation of Endogenous p53 by MDM2 and Human Papillomavirus E6”,Molecular and Cellular Biology, 18(12): 7288-7293 (Dec. 1988).
Galatin et al., “A Nonpeptidic Sulfonamide Inhibits the p53—mdm2 Interaction and Activates p53-Dependent Transcription in mdm2-Overexpressing Cells”, 47(17): 4163-4165 (2004).
Grasberger et al., “Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists that Activate p53 in Cells”,J. Med. Chem., 48(4): 909-912 (2005).
Hainaut et al., “Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects”,Nucleic Acids Research, 25(1): 151-157 (1997).
Hall et al., “Genetic Alterations of Cyclins, Cyclin-Dependent Kinases, and Cdk Inhibitors in Human Cancer”,Advances in Cancer Research, 68: 67-108 (1996).
Honda et al., “Oncoprotein. MDM2 is a ubiquitin ligase E3 for tumor suppressor p53”,FEBS Letters, 420: 25-27 (1997).
Honda et al., “Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase”,Oncogene, 19: 1473-1476 (2000).
Ko et al. “p53: puzzle and paradigm”,Genes&Development, 10: 1054-1072 (1996).
Kojima et al., “MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy”,Blood, 106(9): 3150-3159 (Nov. 1, 2005).
Kussie et al., “Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain”,Science274: 948-953 (Nov. 8, 1996).
Levine, “p53, the Cellular Gatekeeper for Growth and Division”,Cell, 88: 323-331 (Feb. 7, 1997).
Lu et al., “Discovery of a Nanomolar Inhibitor of the Human Murine Double Minute 2 (MDM2)—p53 Interaction through an Integrated, Virtual Database Screening Strategy”,Journal of Medicinal Chemistry, 49(13): 3759-3762 (2006).
May et al., “Twenty years of p53 research: structural and functional aspects of the p53 protein”,Oncogene, 18: 7621-7636 (1999).
Momand et al., “MDM2—master regulator of the p53 tumor suppressor protein”,Gene242 15-29 (2000).
Momand et al., “The mdm-2 Oncogene Product Forms a Complex with the p53 Protein and Inhibits p53—Mediated Transactivation”,Cell, 69: 1237-1246 (Jun. 26, 1992).
Oliner et al., “Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53”,Letters to Nature, 362: 857-860 (Apr. 29, 1993).
Oren, “Decision making by p53: life, death and cancer”,Cell Death and Differentiation, 10: 431-442 (2003).
Roth, “Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein”,The EMBO Journal, 7(2): 554-564 (1998).
Sherr, “The Pezcoller Lecture: Cancer Cell Cycles Revisited”,Cancer Research, 60: 3689-3695 (Jul. 15, 2000).
Stoll et al., “Chalcone Derivatives Antagonize Interactions between the Human Oncoprotein MDM2 and p53”,Biochemistry, 40(2): 336-344 (2001).
Tao et al., “Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53”,Proc. Natl. Acad. Sci. USA, 96: 3077-3080 (Mar. 1999).
Vassilev, “p53 Activation by Small Molecules: Application in Oncology”,Journal of Medicinal Chemistry, 48(14): 4491-4499 (Jul. 14, 2005).
Vassilev et al., In Vivo Activation of the p53 Pathway by Small-Molecule antagonists of “MDM2”,Science, 303: 844-848 (Feb. 6, 2004).
Wu et al., “The p53-mdm-2 autoregulatory feedback loop”,Genes&Development, 7: 1126-1132 (1993).
Zheleva et al., “The p53-Mdm2 Pathway: Targets for the Development of New Anticancer Therapeutics”,Mini Reviews in Medicinal Chemistry, 3(3): 257-270 (2003).
International Search Report for corresponding PCT Application No. PCT/US2007/014958 dated Nov. 23, 2007.
Chemical Abstract No. 1998-035793 for Takeda Chemical Industries Ltd., “Piperidine-Containing Chemokine Receptor Antagonist” (1997) (which is attached to said abstract).
Patent Abstracts of Japan, Publication No. 09249566, Sep. 22, 1997.
Barak et al., “mdm2 expression is induced by wild type p53 activity”,The EMBO Journal, 12(2): 461-468 (1993).
Blaydes et al., “Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2”,Oncogene, 14: 1859-1868 (1997).
Bottger et al., “Identification of novel mdm2 binding peptides by phage display”,Oncogene, 13: 2141-2147 (1996).
Chene, “Inhibition of the p53-MDM2 interaction: Targeting a protein-protein interface”,Molecular Cancer Research, 2: 20-28 (Jan. 2004).
Chene, “Inhibiting the p53-MDM2 interaction: An Important target for cancer therapy”,Nature Reviews, 3: 102-109 (Feb. 2003).
Ding et al., “Structure-Based Design of Potent Non-Peptide MDM2 Inhibitors”,J. Am. Chem. Soc., 127(29): 10130-10131 (2005).
Ding et al., “Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2-p53 Interaction”,Journal of Medicinal Chemistry, 49(12): 3432-3435 (2006).
Donehower et al., “Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours”,Nature, 356: 215-221 (Mar. 19, 1992).
Duncan et al., “Isolation and Structure Elucidation of chlorofusin, a Novel p53-MDM2 Antagonist from aFusariumsp.”,J. Am. Chem. Soc., 123(4): 554-560 (2001).
Fotouhi et al., “Small Molecule Inhibitors of p53/MDM2 Interaction”,Current Topics in Medicinal Chemistry, 5(2): 159-165 (2005).
Bogen Stephane L.
Doll Ronald J.
Gibeau Craig R.
Guo Zhuyan
Lahue Brian Robert
Banerjee Krishna G.
Fetterolf Brandon J
Merck
Pagonakis Anna
LandOfFree
Substituted piperidines that increase P53 activity and the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted piperidines that increase P53 activity and the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted piperidines that increase P53 activity and the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2630949